5^th European Endocrinology and Diabetes Congress

Diabetes and Covid-19

The clinical spectrum of COVID19 is heterogeneous, ranging from mild influenza-like symptoms to acute respiratory distress syndrome, multiple organ failure, and death. Elderly people, diabetes and other comorbidities have been reported as important predictors of morbidity and mortality. Chronic inflammation, increased coagulation activity, impaired immune response, and the potential for direct damage to the pancreas by SARSCoV2 may be one of the underlying mechanisms associated with diabetes and COVID19. There is no conclusive evidence to support the discontinuation of angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker, or thiazolidinedione by COVID 19 in diabetic patients. Hypoglycaemic events should be considered when using chloroquine in these individuals